Skip to content

Study · Randomized controlled trial · n = 65 · 2005

4 results

A prospective randomized study comparing gonadotropin-releasing hormone agonists or gonadotropin-releasing hormone antagonists in couples with unexplained infertility and/or mild oligozoospermia.

Zikopoulos K, Kaponis A, Adonakis G, Sotiriadis A, Kalantaridou S, Georgiou I, Paraskevaidis E

Fertility and sterility1 May 2005Cited by 18 (Europe PMC)

PMID15866569 (opens in a new tab)DOI10.1016/j.fertnstert.2004.11.060 (opens in a new tab)PepBankPUB-15866569
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women undergoing COH for IUI, treatment lasted fewer days with cetrorelix than busereline: medians 9.0 versus 12.0.

    In plain wordsIn women undergoing IUI stimulation, treatment lasted 9.0 days with cetrorelix versus 12.0 with busereline.

    Peptide
    Cetrorelix
    Outcome
    DecreaseTreatment duration
    Study

    n = 65

    Comparator
    Busereline acetate 600 microg per day
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/dAs given in this study (human).

    Measurements

    Median treatment duration
    9 days
    cetrorelix
    Median treatment duration
    12 days
    busereline

    Source sentences

    Summary
    Women in group A required significantly more days of treatment (median: 12.0 vs. 9.0) and significantly more total units of recombinant FSH (median 1,800 vs. 1,550) as compared with the corresponding values of the antagonist group (group B).
    4 context sentences
    Summary · context
    A prospective, randomized trial.
    Summary · context
    Sixty-five patients with unexplained infertility or mild male subfertility undergoing COH for IUI.
    Summary · context
    Twenty-nine women (group A) were randomized to receive 600 microg of busereline acetate per day starting in the midluteal phase of the cycle (long protocol), whereas 36 women (group B) were treated with 0.25 mg/d of the GnRH antagonist Cetrorelix starting from day 6 of the cycle.
    Summary · context
    The starting dose of recombinant FSH was 150 IU in women of both groups.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women undergoing COH for IUI, cetrorelix required less recombinant FSH than busereline: medians 1,550 versus 1,800 units.

    In plain wordsIn women undergoing IUI stimulation, cetrorelix required 1,550 units of recombinant FSH versus 1,800 with busereline.

    Peptide
    Cetrorelix
    Outcome
    DecreaseRecombinant FSH use
    Study

    n = 65

    Comparator
    Busereline acetate 600 microg per day
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/dAs given in this study (human).

    Measurements

    Median recombinant FSH
    1550 units
    cetrorelix
    Median recombinant FSH
    1800 units
    busereline

    Source sentences

    Summary
    Women in group A required significantly more days of treatment (median: 12.0 vs. 9.0) and significantly more total units of recombinant FSH (median 1,800 vs. 1,550) as compared with the corresponding values of the antagonist group (group B).
    4 context sentences
    Summary · context
    A prospective, randomized trial.
    Summary · context
    Sixty-five patients with unexplained infertility or mild male subfertility undergoing COH for IUI.
    Summary · context
    Twenty-nine women (group A) were randomized to receive 600 microg of busereline acetate per day starting in the midluteal phase of the cycle (long protocol), whereas 36 women (group B) were treated with 0.25 mg/d of the GnRH antagonist Cetrorelix starting from day 6 of the cycle.
    Summary · context
    The starting dose of recombinant FSH was 150 IU in women of both groups.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women undergoing IUI stimulation, FSH, LH, E2 and P were significantly higher with cetrorelix than busereline on days 2 and 6.

    In plain wordsIn women undergoing IUI stimulation, the listed hormones were higher with cetrorelix than busereline on days 2 and 6.

    Peptide
    Cetrorelix
    Outcome
    IncreaseSerum FSH, LH, E2 and P on stimulation days 2 and 6
    Study

    n = 65

    Comparator
    Busereline acetate 600 microg per day
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/dAs given in this study (human).

    Source sentences

    Summary
    Serum FSH, LH, E2, and P were significantly higher on the antagonist group on days 2 and 6 of stimulation.
    5 context sentences
    Summary · context
    However, these differences regress until the day of hCG administration.
    Summary · context
    A prospective, randomized trial.
    Summary · context
    Sixty-five patients with unexplained infertility or mild male subfertility undergoing COH for IUI.
    Summary · context
    Twenty-nine women (group A) were randomized to receive 600 microg of busereline acetate per day starting in the midluteal phase of the cycle (long protocol), whereas 36 women (group B) were treated with 0.25 mg/d of the GnRH antagonist Cetrorelix starting from day 6 of the cycle.
    Summary · context
    The starting dose of recombinant FSH was 150 IU in women of both groups.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women undergoing COH for IUI, the higher FSH, LH, E2 and P levels with cetrorelix versus busereline regressed up to the day of hCG administration.

    In plain wordsIn women undergoing IUI stimulation, hormone differences between cetrorelix and busereline regressed up to the day of hCG administration.

    Peptide
    Cetrorelix
    Outcome
    Direction not reportedHormone differences through hCG administration
    Study

    n = 65

    Comparator
    Busereline acetate 600 microg per day
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/dAs given in this study (human).

    Source sentences

    Summary
    However, these differences regress until the day of hCG administration.
    4 context sentences
    Summary · context
    Serum FSH, LH, E2, and P were significantly higher on the antagonist group on days 2 and 6 of stimulation.
    Summary · context
    A prospective, randomized trial.
    Summary · context
    Sixty-five patients with unexplained infertility or mild male subfertility undergoing COH for IUI.
    Summary · context
    Twenty-nine women (group A) were randomized to receive 600 microg of busereline acetate per day starting in the midluteal phase of the cycle (long protocol), whereas 36 women (group B) were treated with 0.25 mg/d of the GnRH antagonist Cetrorelix starting from day 6 of the cycle.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.